Curative effect of sintilimab combined with chemotherapy and its influences on serum VEGF and TGF-β1 in patients with advanced esophageal cancer
Objective To explore the curative effect of sintilimab combined with chemotherapy and its influences on levels of serum vascular endothelial growth factor(VEGF)and transforming growth factor β1(TGF-β1)in patients with advanced esophageal cancer(EC).Methods A total of 120 patients with ad-vanced EC confirmed at Yunnan Cancer Hospital were enrolled between May 2020 and May 2022.Using a ran-dom grouping method,they were divided into an observation group(n=60)and a control group(n=60).The control group received treatment with paclitaxel+fluorouracil+cisplatin,while the observation group received additional treatment with sintilimab.All patients underwent 3 cycles of treatment.The clinical curative effect,levels of serum VEGF,TGF-β1,tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 199(CA199),carbohydrate antigen 50(CA50)],score of Karnofsky performance status(KPS)scores,and inci-dence of adverse reactions were compared between the two groups.After 1 year of follow-up,the survival status of the patients in both groups was compared.Results After treatment,the objective response rate and disease control rate in the observation group were higher than those in the control group(P<0.05).After treatment,lev-els of VEGF and TGF-β1 in both groups decreased,with lower levels observed in the observation group com-pared to the control group(P<0.05).Levels of CEA,CA199,and CA50 also decreased,with the observation group showing lower levels than the than control group(P<0.05).Furthermore,KPS scores increased,with higher scores in the observation group compared to the control group(P<0.05).There was no significant differ-ence in the total incidence of adverse reactions(bone marrow suppression,muscle soreness,gastrointestinal dis-comfort,liver function injury)between the two groups(P>0.05).After 1 year of follow-up,there were 46 sur-vival cases and 14 death cases in the observation group,while there were 35 survival cases and 25 death cases in the control group.The difference in survival status between the two groups was statistically significant(x2=4.596,P=0.032).Conclusion Sintilimab combined with chemotherapy can improve clinical outcomes and functional status in patients with advanced EC.Additionally,it can reduce levels of serum VEGF and TGF-β1.
NETL
NSTL
万方数据
